Benzene Ring In The Alcohol Moiety Patents (Class 514/104)
-
Patent number: 11278533Abstract: Disclosed is a method for protecting an animal from a parasitic invertebrate pest comprising treating an animal orally or by injection with a pesticidally effective amount of a compound of Formula 1, wherein R1 is halogen, C1-C3 haloalkyl or C1-C3 haloalkoxy; R2 is H, halogen, C1-C3 alkyl, C1-C3 haloalkyl or cyano; R3 is H, halogen, C1-C3 haloalkyl or C1-C3 haloalkoxy; R4 is halogen, C1-C3 alkyl, C1-C3 haloalkyl or C1-C3 haloalkoxy; R5 is H, CH3, C2-C4 alkylcarbonyl, C2-C4 haloalkylcarbonyl, C2-C5 alkoxycarbonyl or CH2O(C1-C3 alkyl); R6 is C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl or C3-C6 halocycloalkyl, each group substituted with one R7; or R6 is (CH2)mQ; and Q, R7, R8a and R8b are as defined in the disclosure.Type: GrantFiled: June 26, 2008Date of Patent: March 22, 2022Assignee: E.I. DU PONT DE NEMOURS AND COMPANYInventors: George Philip Lahm, Jeffrey Keith Long, Ming Xu
-
Patent number: 10633573Abstract: The present invention provides a composition useful as a sulfide scale inhibitor for application in oilfield operations, comprising 1) at least one copolymer that comprises as monomers a) 0.1 to 10 mol-%, of structural units derived from vinylphosphonic acid and/or of a salt thereof, b) 40 to 80 mol-% of structural units derived from compounds of the formula (1) c) 1 to 50 mol-% of structural units derived from compounds of the formula (2) in which X is OH or NR3R4, and R3 and R4, independently of one another, are H or C1-C4-alkyl, 2) at least one of tris (hydroxymethyl) phosphine or a tetrakis(hydroxymethyl)phosphonium salt, 3) at least one surfactant, 4) at least one amine or ammonium salt.Type: GrantFiled: March 1, 2016Date of Patent: April 28, 2020Assignee: CLARIANT INTERNATIONAL LTD.Inventors: Cyril Emeka Okocha, Jonathan Wylde
-
Patent number: 10214684Abstract: The present invention relates to friction reducers and to well treatment fluids. In one embodiment there is provided a friction reducing composition comprising (a) a phosphonium compound and (b) a polymeric friction reducer. In a further embodiment there is provided a well treatment fluid comprising a phosphonium compound.Type: GrantFiled: September 30, 2015Date of Patent: February 26, 2019Assignee: BWA WATER ADDITIVES UK LIMITEDInventor: Jeffrey Frank Kramer
-
Patent number: 9839638Abstract: Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents.Type: GrantFiled: January 16, 2013Date of Patent: December 12, 2017Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: William E. Fahl, Nalini Raghavachari, Ming Zhu, John A. Kink
-
Patent number: 9040500Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: GrantFiled: November 28, 2011Date of Patent: May 26, 2015Assignee: OXiGENE, Inc.Inventors: David Chaplin, Bronwyn G. Siim
-
Publication number: 20140051625Abstract: The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicant: MBC Pharma, Inc.Inventors: Alexander Karpeisky, Shawn Patrick Zinnen
-
Patent number: 8653026Abstract: Methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY-720 or an analog are described.Type: GrantFiled: December 20, 2012Date of Patent: February 18, 2014Inventor: Zhonigman Ma
-
Publication number: 20120270831Abstract: This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent.Type: ApplicationFiled: November 28, 2011Publication date: October 25, 2012Applicant: OXIGENE, INC.Inventors: David Chaplin, Bronwyn G. Siim
-
Patent number: 7915238Abstract: The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, therapeutic and prophylactic treatment of cancer, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.Type: GrantFiled: April 26, 2006Date of Patent: March 29, 2011Assignee: Eisai R & D Management Co., Ltd.Inventors: Lynn D. Hawkins, Sally T. Ishizaka
-
Patent number: 7833993Abstract: The present invention is directed to methods of treating diseases and disorders related to immune responses by administering one or more immunomodulatory compounds. In particular, the invention is directed to methods of stimulating and reducing immune responses, treating autoimmune conditions, treating allergic reactions and asthma, and preventing ischemic damage and asthma by administering one or more immunomodulatory compounds.Type: GrantFiled: March 9, 2005Date of Patent: November 16, 2010Assignee: Eisai R&D Management Co., Ltd.Inventors: Lynn D. Hawkins, Sally T. Ishizaka
-
Emu-based formulations for the treatment of damaged skin by inhibiting microbial and fungal activity
Patent number: 7476379Abstract: A formula for use in treating skin aliments includes from about 20 to about 75 wt % emu oil; from about 0.10 to 33 wt % benzyl alcohol; from about 0.10 to about 33 wt % benzoin derivative; from about 0.2 to about 2 wt % allantoin; from about 0.25 to about 1.25 wt % methylparaben; from about 1.0 to about 13 wt % alkyl esters; and from about 0.01 to about 0.30 wt % propylparaben. The formula can be applied to skin of animals or humans with skin ailments. The formula can be applied is various manners, such as through an enhanced oil, a spray, an elastomeric device, a wipe, a lotion, an ointment, a cream, a gel or combinations thereof.Type: GrantFiled: February 13, 2006Date of Patent: January 13, 2009Assignee: Pearson Research & Development LimitedInventors: Maurine Pearson, Teresa Leigh Barr -
Patent number: 7442671Abstract: A composition for protecting wood from decay, mildew and sapstain comprises o-phenylphenol in combination with an alkoxylated amine, wherein the weight ratio of alkoxylated amine to o-phenylphenol ranges from 1:1 to 10:1. Organic or inorganic acids may be added to enhance solubility of the alkoxylated amines.Type: GrantFiled: July 27, 2004Date of Patent: October 28, 2008Assignee: Contechem Inc.Inventor: Eugene L. Mitch
-
Patent number: 7309698Abstract: Compounds and compositions for the delivery of bisphosphonates are provided. Methods of preparation, administration and treatment are provided as well.Type: GrantFiled: March 1, 2002Date of Patent: December 18, 2007Assignee: Emisphere Technologies, Inc.Inventors: Maria Aurora P. Boyd, Steve Dinh
-
Patent number: 6998109Abstract: The present formulation is an analgesic, anesthetic and anti-pruritic formulation with from about 10.0 wt % to about 75.0 wt % Emu oil; from about 10.0 wt % to about 33.0 wt % benzyl alcohol; from about 0.25 wt % to about 5.0 wt % allantoin; from about 0.1 wt % to about 5.0 wt % methylparaben; from about 0.1 wt % to about 2.0 wt % propylparaben; and from about 0.5 wt % to about 4.0 wt % of lidocaine, wherein the formulation is adapted to inhibit microbial activity from Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecalis, Bacillus cereus, Candida albicans, Streptococcus agalactiae or combinations thereof, and wherein the lidocaine relieves pain on the epidermis of humans and animals of skin irritations, wounds, or burns.Type: GrantFiled: January 7, 2004Date of Patent: February 14, 2006Assignee: Pearson Research & Development LimitedInventors: Maurine Pearson, Teresa Leigh Barr
-
Patent number: 6784168Abstract: A synergistic biocide comprises a tris(hydroxymethyl)phosphine or a tetrakis (hydroxymethyl)phosphonium salt and at least one non-surfactant biopenetrant, such as a polymer or copolymer having a plurality of quaternary ammonium groups, a hydrotrope or a syntan, together optionally with a surfactant.Type: GrantFiled: September 5, 2000Date of Patent: August 31, 2004Assignee: Rhodia Consumer Specialties LimitedInventors: Christopher Raymond Jones, Robert Eric Talbot
-
Patent number: 6680307Abstract: The invention relates to use of ibandronic acid (1-hydroxy-3-(N-methyl-N-pentyl)aminopropyl-1,1-diphosphonic acid) or physiologically compatible salts or esters thereof for improving the osseointegration of cement-free anchored endoprostheses. Ibandronate or salts thereof is applied for a short time immediately after insertion of an endoprosthesis, with the surprising result that secondary stability of the implant is obtained in only 5 weeks or less after the operation.Type: GrantFiled: May 31, 2001Date of Patent: January 20, 2004Assignee: Roche Diagnostics GmbHInventors: Frieder Bauss, Andreas A. Kurth
-
Patent number: 6677320Abstract: The present invention relates to a parenteral composition comprising a bisphosphonic acid or a pharmaceutically acceptable salt thereof (bisphosphonate) as active component and a pharmaceutically acceptable chelating agent, processes of the preparation of this composition, and methods of their use in the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, hypercalcemia of malignancy, and metabolic bone disease. The compositions are especially useful for improving the local tolerance of the active component when administered parenterally.Type: GrantFiled: January 11, 2001Date of Patent: January 13, 2004Assignee: Hoffmann-La Roches Inc.Inventors: Anke Diederich, Pierre Goldbach, Thomas Pfister
-
Patent number: 6627660Abstract: Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.Type: GrantFiled: November 16, 1999Date of Patent: September 30, 2003Assignee: New River Pharmaceuticals Inc.Inventors: Thomas Piccariello, Anne F. LeClercq
-
Patent number: 6528040Abstract: An analgesic, anesthetic and antipruritic formulation is provided containing 0.01 to 13 wt % alkyl esters; and 20 to 70 wt % Emu oil; 10 to 33 wt % benzyl alcohol; 10 to 33 wt % benzoin; 0.2 to 2 wt % allantoin; 0.25 to 1.25 wt % methylparaben and 0.01 to 0.30 wt % propylparaben. The formulation may be formulated as a spray or transdermal formula. The formulation may be used for treatment of chronic cutaneous ulcers and burn wounds.Type: GrantFiled: August 24, 2001Date of Patent: March 4, 2003Inventors: Maurine Pearson, Teresa L. Barr
-
Patent number: 6468559Abstract: Oral dosage forms are provided for the administration of a bisphosphonic acid compound in the prevention and treatment of conditions involving calcium or phosphate metabolism, i.e., conditions associated with bone resorption such as osteoporosis, Paget's disease, periprosthetic bone loss, osteolysis, malignant hypercalcemia, metastatic bone disease, multiple myeloma, and periodontal disease. The dosage forms are either enterically coated capsules housing the drug in a liquid or semi-solid carrier, or enterically coated osmotically activated drug delivery devices.Type: GrantFiled: April 28, 2000Date of Patent: October 22, 2002Assignee: Lipocine, Inc.Inventors: Feng-Jing Chen, Mahesh V. Patel
-
Patent number: 6326363Abstract: The object of the invention are novel halogen substituted methylenebisphosphonic acid anhydrides, ester anhydrides, amide anhydrides, and ester amide anhydrides, processes for the preparation of these novel compounds, as well as pharmaceutical preparations comprising these novel compounds.Type: GrantFiled: July 12, 2000Date of Patent: December 4, 2001Assignee: Leiras OyInventors: Esko Pohjala, Heikki Nupponen, Leena Laurén, Ritva Hannuniemi, Jouko Vepsäläinen, Jouni Kähkönen, Tomi Järvinen, Marko Ahlmark
-
Patent number: 6200961Abstract: A low volatile organic compound co-solvent system is disclosed for preparing emulsion concentrates of low melting organophosphorous insecticides wherein the bioefficacy of the insecticide active is significantly enhanced. The co-solvent system comprises a water-soluble ethoxylated fatty acid/rosin acid-nonionic surfactant composition.Type: GrantFiled: December 16, 1998Date of Patent: March 13, 2001Assignee: Aquatrols Corporation of America, Inc.Inventors: Stanley J. Kostka, Rennan Pan
-
Patent number: 6194004Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Type: GrantFiled: November 2, 1999Date of Patent: February 27, 2001Assignee: Merck & Co., Inc.Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
-
Patent number: 6114316Abstract: Tissue-destructive conditions related to excess protemase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.Type: GrantFiled: September 2, 1999Date of Patent: September 5, 2000Assignee: Research Foundation of S.U.N.Y.Inventors: Nungavarm S. Ramamurthy, Lorne M. Golub, Timo A. Sorsa, Olli P. Teronen, Tuula A. Salo
-
Patent number: 5824663Abstract: The invention relates to a method of suppressing human body malodor by utilizing a deodorant composition containing a competitive substrate for the enzymatic creation of axillary body malodor.Type: GrantFiled: March 13, 1996Date of Patent: October 20, 1998Assignee: The Gillette CompanyInventors: Sue Brockett, Clifford O'Neal, Hermes Van Der Lee
-
Patent number: 5616571Abstract: Bisphosphonate, particularly alendronate, can prevent or treat bone loss associated with immunosuppressive therapy, whether or not the immunosuppressive therapy is associated with an organ transplant.Type: GrantFiled: June 6, 1995Date of Patent: April 1, 1997Assignee: Merck & Co., Inc.Inventors: Anastasia G. Daifotis, Ashley J. Yates
-
Patent number: 5614510Abstract: The invention relates to an inositol phosphate containing pharmaceutical composition which comprises a nitrogen-containing compound for improvement of the bioavailability of the inositol phosphate in mammals including man at non-parenteral administration. The invention also covers the use of at least one nitrogen-containing compound for the preparing of an inositol phosphate containing medicament with improved bioavailibility of inositol phosphate in mammals including man at non-parenteral administration.Type: GrantFiled: August 22, 1994Date of Patent: March 25, 1997Assignee: Perstorp ABInventor: Lars Persson
-
Patent number: 5514671Abstract: The invention relates to a method of suppressing human body malodor by utilizing a deodorant composition containing a competitive substrate for the enzymatic creation of axillary body malodor.Type: GrantFiled: July 12, 1993Date of Patent: May 7, 1996Assignee: The Gillette CompanyInventors: Sue B. Lyon, Clifford O'Neal, Hermes van der Lee
-
Patent number: 5438047Abstract: Diphosphates of catecholamines having formula (I) wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and X have the meanings reported in the description, are useful in the therapy of cardiovascular and renal diseases.Type: GrantFiled: March 28, 1994Date of Patent: August 1, 1995Assignee: Zambon Group S.p.A.Inventors: Francesco Santangelo, Cesare Casagrande, Gabriele Norcini
-
Patent number: 5409911Abstract: This invention relates to a prostaglandin-bisphosphonate compound of the formula: ##STR1## and its pharmaceutically acceptable salts. The claimed compounds are effective as delivery agents of prostaglandins to treat osteoporosis and related bone diseases. The claimed compounds also simultaneously deliver a bisphosphonate which inhibits bone resorption and delivers prostaglandins which increase bone formation in vivo.Type: GrantFiled: September 11, 1992Date of Patent: April 25, 1995Assignee: Merck & Co., Inc.Inventors: Peter C. Tyler, Robert N. Young, Gideon A. Rodan
-
Patent number: 5360797Abstract: Novel acids, esters, and salts of phenyl, naphthyl, quinoxalinyl, and biphenyl bisphosphonic acids and 1,2-oxaphosphepins are described. These compounds are useful as antiinflammatory and anti-arthritic agents. Also described are known compounds of the phenyl, naphthyl, quinoxalinyl, and biphenyl bisphosphonate classes which are also useful as antiinflammatory and anti-arthritic agents. Representative compounds include [1,2-phenyldiyl]bis(methylene)bisphosphonic acid tetramethyl ester, [2,3-quinoxalindiyl]bis(methylene)bisphosphonic acid tetramethyl ester, [[3-(propyl)-4-(methoxy)-1,8-naphthalenediyl]bis(methylene)]bisphosphonic acid tetramethyl ester, [2,6-naphthalenediylbis(methylene)bisphosphonic acid tetraethyl ester, and [2,2'-biphenylenebis(methyl)]bisphosphonic acid tetramethyl ester. Representative oxaphosphepins include the preferred 3,4-dihydro-3-methoxy-7-(phenylmethoxy)-1H-naphth[1,8de][1,2]oxaphosphepin -3-oxide.Type: GrantFiled: November 1, 1993Date of Patent: November 1, 1994Assignee: The Upjohn CompanyInventors: Roy A. Johnson, Herman W. Smith
-
Patent number: 5358941Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.Type: GrantFiled: December 2, 1992Date of Patent: October 25, 1994Assignee: Merck & Co., Inc.Inventors: Simon R. Bechard, Kenneth A. Kramer, Ashok V. Katdare
-
Patent number: 5217964Abstract: The present invention relates to certain polyamine thiols which are useful as radioprotective agents.Type: GrantFiled: January 23, 1991Date of Patent: June 8, 1993Assignee: Merrell Dow Pharmaceuticals Inc.Inventors: Michael L. Edwards, Ronald D. Snyder
-
Patent number: 4643764Abstract: In a process of encapsulating water-immiscible material within discrete capsules of polyurea without addition of a second reactant, whereby hydrolysis of an isocyanate monomer to form an amine takes place which in turn reacts with another isocyanate monomer to form polyurea, which comprises the steps(a) providing at room temperature a dispersion of(i) a water-immiscible phase comprising the water-immiscible material to be encapsulated and organic polyisocyanates in(ii) an aqueous phase comprising a solution of water, a surfactant and a protective colloid; and(b) heating and maintaining said dispersion in a temperature range of about 40.degree. C. to about 90.degree. C.Type: GrantFiled: January 31, 1985Date of Patent: February 17, 1987Assignee: Stauffer Chemical CompanyInventor: Herbert B. Scher